Kyorin Group has formulated a new long-term vision “Vision 110” (FY2023-FY2032) and has began a new medium-term business plan “Vision 110 -Stage 1-” (FY2023-FY2025).
The background of formulation for the Long-term vision “Vision 110”
The Kyorin Group has formulated a long-term vision "HOPE100" that looks ahead to 2023, the 100th anniversary of the founding of its core company, KYORIN Pharmaceutical Co., Ltd., and has promoted the medium-term business plan "HOPE100 -Stage 3-” (FY2020-FY2023), which is the final year of HOPE100, by dividing the period (FY2010-FY2023) into three stages.
In the meantime, however, as the external environment surrounding our business some unexpected events such as annual NHI drug price revisions (mid-year revisions) due to the further promotion of measures to curb medical and drug costs, and the suppression by patients of visiting medical institutions due to the COVID-19 pandemic. These events have had a significant impact on the management of our group.
On the other hand, in terms of the internal environment, in addition to the launches of new drugs that we expect to become growth drivers, new businesses, such as the diagnostics business, are starting to take off.
Under these circumstances, in fiscal year 2023, the 100th anniversary of our founding, we have renovated our group structure. At the same time, we have completed our long-term vision "HOPE100" one year ahead of schedule, and have decided to formulate and launch a new long-term vision "Vision 110" and a new medium-term business plan "Vision 110 -Stage1-”
Change of the external environment
- Decline birthrate and aging population
- Increase geopolitical risk
- Initiative for the sustainability issues
- Promote of measures to curb medical and drug cost
- Progress of personalized medicine and specialty field
- Increasing need for diagnosis and prevent
- Change of way of providing information to medical professionals
- Progress of DX in medical care
- Increase difficulty of drug discovery
- Diversification and increasingly complex of modality
- Ensure reliability against pharmaceutical company
New drugs business
- Creation of new drugs
- Expansion of pipeline, DTx development
- Acceleration of growth of new drugs
Health care related business
- Promote generic drug business
- Stable supply, stable procurement of API
- Enhancement of the diagnostics business
- Improve cost competitiveness
- Respond to environmental issue, compliance, governance, etc.
About new long-term vision “Vision 110”
We have formulated “Vision 110”, a new long-term vision for the 110th anniversary of our founding. Our vision is to become “a company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value new drugs that meet medical needs”. We will strive to achieve this goal.
Vision for 110th anniversary
- Our goal
A company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value new drugs that meet medical needs
10 years: FY2023 - FY2032
- Medium-term business plan
- Stage1FY2023 - FY2025
- Stage2FY2026 - FY2029
- Stage3FY2030 - FY2032